Masaki Kanazu
Overview
Explore the profile of Masaki Kanazu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
476
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kinehara Y, Shiroyama T, Tamiya A, Tamiya M, Minami S, Kanazu M, et al.
JTO Clin Res Rep
. 2023 Nov;
4(11):100586.
PMID: 38029024
Introduction: Durvalumab consolidation therapy is the standard of care after concurrent chemoradiotherapy (CRT) for stage III NSCLC. Immune-related pneumonitis during durvalumab treatment is potentially fatal; however, information is lacking regarding...
2.
Kuge T, Shiroyama T, Tamiya A, Tamiya M, Kanazu M, Kinehara Y, et al.
JTO Clin Res Rep
. 2023 Jun;
4(5):100505.
PMID: 37284296
Introduction: Durvalumab maintenance therapy after definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III NSCLC. Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of...
3.
Shimokawa M, Kanazu M, Saito R, Mori M, Tamura A, Okano Y, et al.
Thorac Cancer
. 2023 Apr;
14(17):1597-1605.
PMID: 37073452
Background: Previous trials suggest that older adults with non-small cell lung cancer (NSCLC) derive benefit from platinum doublet combination therapy, but its superiority is controversial. Although geriatric assessment variables are...
4.
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, et al.
JAMA Netw Open
. 2023 Feb;
6(2):e230698.
PMID: 36826813
Importance: Chemoimmunotherapy is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). However, whether findings from pivotal trials can be extrapolated to the clinical practice setting...
5.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, et al.
Eur J Cancer
. 2022 Dec;
179:15-24.
PMID: 36470023
Introduction: Although osimertinib is a standard first-line treatment for patients with advanced-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, the incidence rate of pneumonitis associated...
6.
Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, et al.
Thorac Cancer
. 2022 Nov;
14(2):168-176.
PMID: 36408699
Background: The therapeutic efficacy of cytotoxic anticancer drugs has been reported to be enhanced after immune checkpoint inhibitors (ICI) in non-small cell lung cancer; however, it is unclear whether the...
7.
Kanazu M, Shimokawa M, Saito R, Mori M, Tamura A, Okano Y, et al.
J Geriatr Oncol
. 2022 Aug;
13(8):1216-1222.
PMID: 36008273
Introduction: Previous studies have developed risk stratification schemas to assess systemic therapy toxicity. However, it is controversial which geriatric assessment variables should be used to assess the individual risk of...
8.
Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Taniguchi Y, et al.
Lung Cancer
. 2022 Jul;
171:3-8.
PMID: 35863254
Objective: Durvalumab was safe and effective in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in a phase 3 trial (PACIFIC trial). Although a...
9.
Akazawa Y, Yoshikawa A, Kanazu M, Yano Y, Yamaguchi T, Mori M
Thorac Cancer
. 2022 Jul;
13(17):2450-2458.
PMID: 35820673
Background: Since 2015, immune checkpoint inhibitors have been a clinical treatment strategy for patients with advanced or recurrent non-small cell lung cancer (NSCLC). However, the relationship between immune-related adverse event...
10.
Kawachi H, Tamiya M, Taniguchi Y, Yokoyama T, Yokoe S, Oya Y, et al.
JTO Clin Res Rep
. 2022 Jun;
3(7):100355.
PMID: 35769388
Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard...